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DOI 10.1016/j.ccr.2010.05.025SUMMARYWe have unveiled a synthetic lethal interaction between K-Ras oncogenes andCdk4 in a mouse tumor model
that closely recapitulates human non-small cell lung carcinoma (NSCLC). Ablation of Cdk4, but not Cdk2 or
Cdk6, induces an immediate senescence response only in lung cells that express an endogenous K-Ras
oncogene. No such response occurs in lungs expressing a single Cdk4 allele or in other K-Ras-expressing
tissues. More importantly, targeting Cdk4 alleles in advanced tumors detectable by computed tomography
scanning also induces senescence and prevents tumor progression. These observations suggest that robust
and selective pharmacological inhibition of Cdk4 may provide therapeutic benefit for NSCLC patients
carrying K-RAS oncogenes.INTRODUCTION
Genetic interrogation of the cell cycle in mice has revealed that
most cell types proliferate well in the absence of the interphase
Cdks, Cdk2, Cdk4, and Cdk6 (Santamarı´a et al., 2007). A fourth
interphase Cdk, Cdk3, is inactivated by a naturally occurring
mutation in most strains of laboratory mice, thus indicating that
it is dispensable for normal homeostasis (Ye et al., 2001).
However, interphase Cdks, either individually or in combination,
are essential to drive proliferation of certain cell types during
specific developmental stages (Malumbres and Barbacid,
2009). For instance, Cdk4 is essential for proliferation of
insulin-producing beta cells only during postnatal developmentSignificance
CDK inhibitors have failed as anti-cancer agents due to their lim
indicates that whereas Cdk1 is essential for the mammalian c
essential for proliferation of highly specialized cells. Here, we
that Cdk4, but not Cdk2 or Cdk6, is essential for proliferation
date, a selective CDK4 inhibitor has shown no significant thera
tumors. Our results suggest that this compound as well as m
against K-RAS-driven lung adenocarcinomas.(Rane et al., 1999; Tsutsui et al., 1999). Likewise, mice lacking
Cdk2 and Cdk4 complete embryonic development to die at birth
due to a defect in the number of cardiomyocytes (Barrie`re et al.,
2007). Yet, ablation of Cdk2 and Cdk4 in adult mice does not
result in obvious pathological conditions except for hypergly-
cemia, a direct consequence of the essential role of Cdk4 for
proliferation of postnatal pancreatic beta cells (Barrie`re et al.,
2007). These findings have raised the possibility that interphase
Cdks may also be selectively required by tumor cells depending
on their cellular origin and, possibly, their pathogenetic profile
(Malumbres and Barbacid, 2009).
Previous studies have provided evidence that Cdk4 and its
cognate cyclin, Cyclin D1, are required for the development ofited activity and significant toxicity. Recent genetic evidence
ell cycle, interphase Cdks, Cdk2, Cdk4, and Cdk6, are only
provide genetic and pharmacological evidence indicating
of lung cells providing they express a K-Ras oncogene. To
peutic benefit in clinical trials against leukemias and breast
ore potent CDK4 inhibitors should be tested in clinical trials
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Figure 1. The Proliferative Advantage
Conferred by an Endogenous K-RasG12V
Oncogene Requires Expression of Inter-
phase Cdks
(A) Immortalization of primary MEFs follow-
ing a 3T3 protocol including those derived
from K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk2+/+ (open
circles) and K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk2/
(solid circles) littermates; K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk4+/+ (open squares) and
K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk4/ (solid
squares) littermates; K-Ras+/LSLG12Vgeo;RERTert/ert;
Cdk6+/+ (open triangles) and K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk6/ (solid triangles) littermates.
Cells were cultivated in DMEM media supple-
mented with 10% FBS and 600 nM 4OHT.
(B) Growth curves of the above primary MEFs culti-
vated in DMEM media supplemented with 2% FBS
and 600 nM 4OHT. Symbols are as those
described in (A).
(C) Growth curves of foci derived from (left)
Cdk2lox/lox MEFs and (right) Cdk4frt/frt MEFs trans-
formed by H-Ras and E1a oncogenes and infected
with adenoviruses encoding (left) Cre and (right)
Flpe recombinases (solid symbols) or GFP (empty
symbols). Inserts show Western blot analysis of
Cdk2 and Cdk4 protein levels at the conclusion
of the experiment. Data shown represent mean ±
SD, n = 3.
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Cdk4, a Therapeutic Target in K-Ras-Driven NSCLCbreast tumors induced by ErbB-2 (Landis et al., 2006; Yu et al.,
2006). Likewise, mice null for Cdk4 are resistant to skin tumors
induced by the two-stage DMBA+TPA carcinogenesis protocol
or by expression of a K5-Myc transgene (Rodriguez-Puebla
et al., 2002; Miliani de Marval et al., 2004). The fact that these
experiments were carried out with mice lacking Cdk4 in
their germ line makes it impossible to determine whether
Cdk4 is required for initiation of tumorigenesis, for instance, by
decreasing the number of susceptible cells, or for tumor progres-
sion by limiting the proliferative properties of cancer cells. On the
contrary, ablation of Cdk2 in mice lacking its putative inhibitor, the
p27Kip1 tumor suppressor, had no effect on tumor development
(Martı´n et al., 2005). Thus, indicating that Cdk2 does not mediate
the tumor suppressor properties of p27Kip1 in spite of the well-
known interaction between these molecules in in vitro assays.
In this study, we have interrogated the role of the interphase
Cdks in the development of non-small cell lung carcinomas
(NSCLC) driven by an endogenous K-Ras oncogene (Guerra
et al., 2003) with the ultimate goal of identifying potential
synthetic lethal interactions between oncogenic K-Ras signaling
and loss of Cdk activity. Identification of such synthetic interac-
tions may serve to design better therapeutic strategies to treat
K-RAS-driven NSCLC in human patients.
RESULTS
Loss of Individual Cdks Abrogate the Proliferative
Advantage Induced by K-RasG12V in Mouse Cells
To evaluate the contribution of individual interphase Cdks to
the various phenotypes triggered by endogenous K-Ras64 Cancer Cell 18, 63–73, July 13, 2010 ª2010 Elsevier Inc.oncogenes, we first established primary MEFs derived from
K-Ras+/LSLG12Vgeo;RERTert/ert mice (Guerra et al., 2003) deficient
for Cdk2, Cdk4, or Cdk6 (Ortega et al., 2003; Malumbres et al.,
2004; Barrie`re et al., 2007). As previously reported, expression
of the resident K-RasG12V oncogene upon exposure to 4OHT
bypassed the replicative senescence response displayed by
MEFs during ‘‘culture shock’’ before they become adapted to
grow in vitro (Guerra et al., 2003; Tuveson et al., 2004). Ablation
of any of the interphase Cdks ‘‘restored’’ this senescence
response, albeit they did not prevent cells from become immortal
(Figure 1A). K-RasG12V expression also allowed these cells to
proliferate under limiting serum availability (2% of FBS), a condi-
tion that does not support expansion of normal MEFs (Tuveson
et al., 2004). Interestingly, elimination of any individual interphase
Cdk eliminated the ability of these K-RasG12V-expressing MEFs
to grow under limiting serum conditions (Figure 1B).
Fully transformed MEFs were also sensitive to loss of inter-
phase Cdks. Conditional Cdk2lox/lox or Cdk4frt/frt MEFs (Ortega
et al., 2003; Barrie`re et al., 2007) were transformed by ectopic
expression of H-Ras and E1a oncogenes. Individual foci were
subsequently infected with adenoviral particles expressing Cre
or Flpe recombinases to eliminate the conditional Cdk2 or Cdk4
alleles, respectively (Figure 1C). Ablation of these Cdk alleles sig-
nificantly reduced the proliferation of transformed MEFs. These
observations are specific for transformed MEFs given that
acute deletion of Cdk2 or Cdk4 in nontransformed Cdk2lox/lox or
Cdk4frt/frt MEFs had no significant effect on their proliferative
properties (Ortega et al., 2003; Barrie`re et al., 2007). These results
suggest that the proliferative advantages conferred in vitro by
Ras oncogenes require a full complement of interphase Cdks.
Figure 2. Knockdown of Interphase CDKs
Hinders Proliferation of Human NSCLC
Cell Lines Harboring K-RAS Oncogenes
(A) Human NSCLC cell lines carrying K-RAS
oncogenes were infected with lentiviral particles
expressing shRNAs against CDK2 (light-gray
boxes), CDK4 (dark-gray boxes), or CDK6 (black
boxes) and allowed to proliferate in culture for
7 days. Total cell numbers were monitored and
normalized compared to those of the correspond-
ing tumor cell line infected with lentiviral particles
expressing a control scramble shRNA (open
boxes). Data shown represent mean ± SD, n = 3.
(B) Same as in (A) except that the human NSCLC
cell lines carried wild-type K-RAS alleles.
(C) Western blot analysis of the infected cultures to
assess the efficiency of shRNA-mediated knock-
down. GAPDH is shown as a loading control.
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Require the Full Complement of Interphase CDKs
Next, we examined whether human tumor cells carrying K-RAS
oncogenes may also require selective interphase CDKs for
proliferation. Ten human NSCLC tumor cell lines, five of which
carrying K-RAS oncogenes (Uchiyama et al., 2003; Blanco
et al., 2009), were grown in the presence of shRNAs specific
for CDK2, CDK4, or CDK6 (Figures 2A and 2B). These shRNAs
inhibited the expression of their cognate CDK alleles by at least
90% (Figure 2C). As illustrated in Figure 2A, four of the five
NSCLC tumor cell lines carrying K-RAS oncogenes also required
the full complement of interphase CDKs for proliferation since
expression of any of the shRNAs was sufficient to block prolifer-
ation. The resistant H460 cell line is known to express very low
levels of the oncogenic K-RAS protein (Uchiyama et al., 2003),
a property that may explain its tolerance to proliferate in the
absence of CDK2, CDK4, or CDK6 (Figure 2A). However, the
five NSCLC cell lines lacking K-RAS oncogenes were unaffected
by losing expression of single CDKs, with the possible exception
of Calu-3 (Figure 2B). These observations resemble those
obtained with mouse cells and suggest that human NSCLC cells
carrying K-RAS oncogenes also become addicted to the full
complement CDK activity, at least in culture.
Tumor Development in Mice Devoid of Individual
Interphase Cdks
These results raised the possibility that decreasing overall Cdk
activity by ablating or knocking down individual Cdks may atten-Cancer Cell 18, 6uate the oncogenic properties of K-Ras
oncogenes in vivo. To explore this possi-
bility, we crossed K-Ras+/LSLG12Vgeo;
RERTert/ert mice with animals null for
each of the interphase Cdks including
Cdk2/, Cdk4/, and Cdk6/ (Ortega
et al., 2003; Malumbres et al., 2004;
Barrie`re et al., 2007). These strains were
also deficient for the additional inter-
phase Cdk, Cdk3, because of a naturally
occurring mutation that results in a
premature stop codon (Ye et al., 2001).K-Ras+/LSLG12Vgeo;RERTert/ert mice treated at weaning with
4OHT to allow expression of the resident K-RasG12V oncogene
develop adenomas and NSCLCs that closely recapitulate those
of human origin. Compound K-Ras+/LSLG12Vgeo;RERTert/ert mice
carrying either of the three Cdk null alleles were treated with
limiting doses of 4OHT to prevent the induction of an excessive
number of focal tumors that may obscure the natural develop-
ment of NSCLCs in an effort to mimic those events that take
place in human patients. As illustrated in Figure 3A, Cdk6
deficiency did not result in significant lifespan extension in
K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk6/ mice as compared with
those expressing Cdk6 (50% survival at 40 weeks). Moreover,
a cohort of K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk6/ mice sacri-
ficed 6 months after 4OHT administration revealed similar
tumor number, size, and grade than those observed in control
K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk6+/+ animals (Figure 3B).
In the absence of Cdk2, K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk2/
mice displayed an increased lifespan of 8 weeks compared
with those animals expressing Cdk2 (34 versus 42 weeks, a
23% increase). This effect was likely to be a consequence of the
reduced tumor burden (50%) observed in K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk2/ mice compared with K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk2+/+ littermate controls (Figure 3C). Tumor reduc-
tion was similar among low- and high-grade lesions, suggesting
that ablation of Cdk2 may have an inhibitory effect on K-Ras-
induced tumor initiation rather than on tumor progression
(Figure 3D). It could be argued that these tumors do not require
expression of Cdk6 or Cdk2 because these knockout strains3–73, July 13, 2010 ª2010 Elsevier Inc. 65
Figure 3. K-RasG12V-Induced NSCLC in
Mice Lacking Cdk2 or Cdk6
(A) Survival curve of K-Ras+/LSLG12Vgeo;RERTert/ert;
Cdk6+/+ (open triangles) and K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk6/ (solid triangles) littermates
treated intraperitoneally with 4OHT (1 mg twice
a week for 2 weeks) at weaning.
(B) Number and grade of lung tumors present in
K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk6+/+ (open bars;
n = 6) and K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk6/
(solid bars; n = 7) littermates sacrificed 6 months
after 4OHT treatment. Data shown represent
mean ± SD.
(C) Survival curve of K-Ras+/LSLG12Vgeo;RERTert/ert;
Cdk2+/+ (open circles) and K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk2/ (solid circles) littermates
treated intraperitoneally with 4OHT at weaning.
(D) Number and grade of lung tumors present in
K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk2+/+ (open bars;
n = 6) and K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk2/
(solid bars; n = 6) littermates sacrificed 6 months
after 4OHT treatment. Data shown represent
mean ± SD. See also Figure S1.
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Cdk4, a Therapeutic Target in K-Ras-Driven NSCLChave developed compensatory mechanisms during embryonic
or postnatal development. Thus, we decided to interrogate
whether NSCLC that developed in the presence of Cdk2 may
be more sensitive to acute ablation of this kinase. As illustrated
in Figure S1 (available online), exposure of K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk2lox/lox mice to 4OHT for 3 months resulted in
limited increased survival that closely resembled that observed
in mice lacking Cdk2 in their germ line (Figure S1A). Likewise,
the relative reduction in tumor burden and tumor grade in
these mice was very similar to that observed in K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk2/ animals (Figure S1B). These results were not
due to limited Cre-mediated recombination (Figure S1C). More-
over, all tumors tested displayed complete ablation of the condi-
tional Cdk2lox alleles (Figure S1D).
Cdk4 null mice develop diabetes and die at approximately
8 months of age (Rane et al., 1999; Tsutsui et al., 1999). This
defect prevented us from studying the impact of Cdk4 deficiency
on the survival of K-Ras+/LSLG12Vgeo;RERTert/ert mice because we
did not wish to bias the study by using the low percentage of mice
(mostly female) that survive >1 year of age. Thus, we decided to
examine a cohort of K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk4/
mice along with their K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk4+/+ litter-
mate controls, 6 months after induction of K-RasG12V expression.
As illustrated in Figure 4A, we observed a significant reduction
in tumor burden regardless of the glycemic state of the mice
(data not shown). Moreover, all tumors were benign lesions
(grades I and II) (Figure 4B). We also observed a dramatic reduc-
tion in the number of K-RasG12V-expressing cells in the normal
parenchyma, as determined by surrogate b-Geo expression
(Figure 4A). These results indicate that ablation of Cdk4 selec-
tively decreases the number of K-RasG12V-expressing cells and
hinders the development of K-RasG12V-induced NSCLCs.
Lack of Cdk4 Prevents Development of Aggressive Lung
Adenocarcinomas
It has been reported that the wild-type K-Ras protein has tumor
suppressor properties (Zhang et al., 2001) and is frequently lost66 Cancer Cell 18, 63–73, July 13, 2010 ª2010 Elsevier Inc.in advanced mouse and human lung tumors (Li et al., 2003; To
et al., 2008). We have generated a mouse model to study this
phenomenon by replacing the wild-type K-Ras allele by a condi-
tional K-Raslox allele in K-Ras+/LSLG12Vgeo;RERTert/ert mice. The
resulting K-Raslox/LSLG12Vgeo;RERTert/ert mice developed much
more aggressive lung tumors than those carrying a wild-type
K-Ras allele (50% survival at 25 versus 42 weeks) (C.G., D.S.
and M.B., unpublished data). Thus, we decided to use this strain
to test the effect of Cdk4 deficiency on tumor development. As
illustrated in Figures 4C and 4D, 6 months after the administra-
tion of 4OHT, lungs of K-Raslox/LSLG12Vgeo;RERTert/ert mice dis-
played NSCLCs of large size, most of which were diagnosed
as high grade (mainly grades III and IV with some occasional
grade V tumor). However, in K-Raslox/LSLG12Vgeo;RERTert/ert;
Cdk4/ mice the number of lung tumors was reduced 6- to
8-fold (Figure 4D). Moreover, tumor progression was also
affected by the absence of Cdk4 since K-Raslox/LSLG12Vgeo;
RERTert/ert;Cdk4/ mice displayed some grade III adenocarci-
nomas but not grade IV or grade V (metastatic) tumors
(Figure 4D). The overall number of K-RasG12V-expressing cells
was also significantly decreased in these mice.
K-RasG12V Expression in Cdk4/ Lungs Activates
an Immediate Senescence Response
Next, we interrogated how loss of Cdk4 expression decreased
the overall number of K-RasG12V-expressing lung cells. First,
we examined the number of adult lung cells positive for the surro-
gate b-Geo marker 2 weeks after a single injection of 4OHT,
a time when most b-Geo-positive cells appeared as individual
cells. As illustrated in Figures 5A and 5B, at this time point lungs
showed similar number of K-RasG12V-positive cells, regardless
of whether they expressed Cdk4 or not. Two weeks later, how-
ever, the levels of K-RasG12V-positive cells in K-Raslox/LSLG12Vgeo;
RERTert/ert;Cdk4+/+ lungs were 8- to 10-fold higher than those
observed in lungs of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/
mice. Moreover, most b-Geo-positive cells in Cdk4+/+ lungs
appeared in clusters of 30–100 cells, suggesting that they had
Figure 4. Effect of Cdk4 Deficiency on
K-RasG12V-Induced NSCLC
(A) Whole-mount X-Gal (left) and H&E staining
(right) of representative lung specimens of
7-month-old K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk4+/+
and K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk4/ litter-
mates treated with 4OHT at weaning. Blue staining
corresponds to K-RasG12V-expressing cells. The
scale bar represents 2 mm.
(B) Number and grade of lung tumors present in
K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk4+/+ (open bars;
n = 6) and K-Ras+/LSLG12Vgeo;RERTert/ert;Cdk4/
(solid bars; n = 5) littermates sacrificed 6 months
after 4OHT treatment. Data shown represent
mean ± SD. ***p < 0.001.
(C) Whole-mount X-Gal (left) and H&E staining
(right) of representative lung specimens of
7-month-old K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+
and K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ litter-
mates treated with 4OHT at weaning. The large
size of the lobule obtained from K-Ras+/LSLG12Vgeo;
RERTert/ert;Cdk4+/+ is due to tumor burden. The
scale bar represents 2.5 mm.
(D) Number and grade of lung tumors present in
K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+ (open bars;
n = 5) and K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/
(solid bars; n = 5) littermates sacrificed 6 months
after 4OHT treatment. Data shown represent
mean ± SD. ***p < 0.001.
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expression (Figure 5A). In contrast, b-Geo-positive cells in the
Cdk4/ lungs remained mostly as single cells or as very small
clusters of two to four cells (Figure 5A). These results indicate
that expression of K-RasG12V failed to induce sustained prolifer-
ation of lung cells in the absence of Cdk4.
These observations were confirmed by 5-bromo-20-deoxyuri-
dine (BrdU) labeling (Figure 5C). One week after 4OHT treatment,
15% of K-RasG12V-positive cells were labeled with BrdU inde-
pendently of their Cdk4 status (data not shown). A week later, the
percentage of BrdU-positive cells in Cdk4+/+ lungs increased to
37% (Figure 5D). However, only 3.5% of the K-RasG12V-express-
ing cells in lungs lacking Cdk4 displayed BrdU staining. Thirty
days after 4OHT treatment, these percentages became 46%
and 2.2%, respectively (Figure 5D). These observations are
unlikely to be due to apoptosis of Cdk4/ lung cells given that
we failed to detect any positive staining for active Caspase 3A
(data not shown).
Next, we focused our attention on cellular senescence as
a potential mechanism responsible for the lack of proliferation
of K-RasG12V-expressing Cdk4/ lung cells. Previous studies
have shown that K-RasG12V-induced adenomas express senes-
cence-associated (SA) endogenous b-Galactosidase activity
(Collado et al., 2005). Yet, it is unknown when this senescence
marker appears during adenoma formation and whether senes-
cence plays a role in preventing cell proliferation during preade-
noma stages. As illustrated in Figure 6A, only lung sections of
Cdk4-deficient mice displayed senescent cells upon K-RasG12V
expression. No SA-b-Gal staining could be observed in lung
sections of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+ mice (Fig-
ure 6A) or in Cdk4/ animals lacking the K-RasG12V oncogene
(data not shown). The percentage of senescent cells in Cdk4/lungs (4%) was similar to the number of cells known to express
the endogenous K-RasG12V before clonal expansion (compare
Figures 5B with Figure 6B). Such a result suggests that most
K-RasG12V-expressing cells in Cdk4/ lungs undergo senes-
cence instead of initiating a proliferative response.
Induction of senescence appeared to be exquisitely specific
for lung cells. As illustrated in Figure 6C, no SA-b-Gal staining
could be observed in colon sections of K-Raslox/LSLG12Vgeo;
RERTert/ert;Cdk4/ mice in spite of wide expression of
K-RasG12V, as determined by surrogate b-Geo staining.
Similar results were observed in other K-RasG12V-expressing
tissues including pancreas, stomach, and thymus (data not
shown). Interestingly, none of these tissues undergo tumor
development, or even hyperplasia, as a consequence of
K-RasG12V expression even in the presence of Cdk4. Finally,
lungs from K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk2/ mice
treated in parallel with 4OHT also lacked senescent cells rein-
forcing the notion that senescence is a Cdk4-specific
response (Figure 6D).
In vitro, oncogene-induced senescence is mediated by activa-
tion of the DNA damage response (Di Micco et al., 2006; Bart-
kova et al., 2006; Mallette et al., 2007) and is accompanied by
loss of Cyclin D1 expression (Pontano et al., 2008). K-RasG12V
expression in Cdk4/ lungs also led to the appearance of
g-H2AX-positive cells with a frequency similar to those positive
for SA-b-Gal (Figures 6E and 6F). Likewise, expression of Cyclin
D1 selectively disappeared in K-RasG12V;Cdk4/ cells 1 month
after exposure to 4OHT (Figures 6G and 6H). In summary,
expression of an endogenous K-RasG12V oncoprotein in lung
cells lacking Cdk4 induces an immediate senescence response
that prevents cell proliferation, and as a consequence tumor
development.Cancer Cell 18, 63–73, July 13, 2010 ª2010 Elsevier Inc. 67
Figure 5. Lack of K-RasG12V-Induced Proliferation in Lung Cells Devoid of Cdk4
(A and B) Detection (A) and quantification (B) of K-RasG12V-expressing cells (based on the expression of the b-Geo surrogate marker, b-Geo+ cells) in lung
sections of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+ (open bars; n = 4) and K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ (solid bars; n = 4) littermates, 15 and
30 days after exposure to a single dose of 4OHT (1 mg) applied at weaning. Data shown represent mean ± SD. ***p < 0.001. The scale bar represents 50 mm (A).
(C and D) Detection (C) and quantification (D) of b-Geo+ cells positive for BrdU staining (BrdU+ cells) on X-Gal-stained whole-mount lung sections of
K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+ (open bars; n = 4) and K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ (solid bars; n = 4) littermates, 15 and 30 days after exposure
to 4OHT. BrdU was injected 24 hr prior to the analysis. Data shown represent mean ± SD. ***p < 0.001. The scale bar represents 20 mm (C).
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NSCLC
To evaluate whether Cdk4 may also be required for progression
of pre-existing tumors, we replaced a Cdk4 null allele by
a conditional Cdk4frt allele to allow Cdk4 ablation in a
temporally controlled manner (Barrie`re et al., 2007). The resulting
K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/frt mice developed tumors
with similar kinetics to those carrying wild-typeCdk4 alleles, indi-
cating that 50% inhibition of Cdk4 expression has no effect
on tumor development (data not shown). Tumor-bearing mice,
as determined by computed tomography (CT) scanning (tumor
size >1 mm diameter) were inoculated with adenoviruses
expressing Flpe recombinase (Ad-Flpe) or control green fluores-
cent protein (Ad-GFP). Three-dimensional reconstruction of the
CT scans 3 months after Ad-Flpe infection revealed a reduced
number of lesions with significantly smaller size as those present
in mice inoculated with Ad-GFP (Figure 7A). The average volume
of the tumors in mice exposed to Ad-Flpe was approximately
one-fifth of those present in Ad-GFP treated mice (n = 5)68 Cancer Cell 18, 63–73, July 13, 2010 ª2010 Elsevier Inc.(Figure 7B). In addition, the number of grade III–IV lesions
decreased significantly (Figure 7C). Most importantly, all tested
high-grade tumors that progressed after Ad-Flpe exposure
retained Cdk4 expression (Figure 7D) because of lack of excision
of the conditional allele (data not shown). These results indicate
that Cdk4 expression is an essential requirement for progression
of already established K-RasG12V-driven tumors.
Tumors in which the Cdk4frt allele was efficiently excised
displayed a remarkable reduction in BrdU incorporation just
2 weeks after being exposed to Ad-Flpe (Figure 7E, upper
panels). Moreover, these tumors showed widespread SA-b-Gal
staining indicating that most tumor cells have entered a senes-
cent state upon loss of Cdk4 expression (Figure 7E, lower
panels). Protein extracts from microdissected lung lesions
showing significant reduction of Cdk4 expression displayed
upregulation of senescence markers such as p19Arf and
p53P-Ser15 (Palmero et al., 1998; Webley et al., 2000) (Figure 7F).
None of these markers were observed in tumors exposed to
Ad-GFP (Figure 7F). Onset of the senescence response was
Figure 6. Cdk4 Selectively Inhibits K-RasG12V-Induced Senescence in Lung Cells
(A) Detection and (B) quantification of senescence-associated b-galactosidase (SA-b-Gal)-positive cells in lung sections of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+
(open bars; n = 4) and K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ (solid bars; n = 4) littermates, 15 and 30 days after exposure to 4OHT. Data shown represent mean ±
SD. *p = 0.012; **p = 0.0017.
(C) Detection of K-RasG12V expression (based on its surrogate marker b-Geo) (left) and absence of senescence-associated b-galactosidase (SA-b-Gal) (right) in
colonic crypts of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ mice.
(D) Detection of K-RasG12V expression (based on its surrogate marker b-Geo) (left) and absence of senescence-associated b-galactosidase (SA-b-Gal) (right) in
lungs of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk2/ mice.
(E) Detection and (F) quantification of g-H2AX-positive cells in lung sections of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+ (open bars; n = 4) and
K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ (solid bars; n = 4) littermates, 15 and 30 days after exposure to 4OHT. Arrowheads mark cells with positive staining.
Data shown represent mean ± SD. **p = 0.006; ***p < 0.001.
(G) Detection and (H) quantification of b-Geo+ cells positive for Cyclin D1 expression (CycD1+ cells) on X-Gal stained whole-mount lung sections of
K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+ (open bars; n = 4) and K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ (solid bars; n = 4) littermates, 15 and 30 days after expo-
sure to 4OHT. Data shown represent mean ± SD. *p < 0.001. Scale bars represent 50 mm (A, C, and D) and 20 mm (E and G).
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(CD3+ cells) and cells of neutrophil-granulocyte lineage (MPO+
cells) (Figure S2) but not by B-lymphocytes (data not shown).
In summary, advanced K-RasG12V-driven lung tumors require
expression of Cdk4 to avoid the onset of senescence followed
by activation of an immune response, two events that ultimately
result in effective inhibition of tumor progression.
Cdk4 Inhibitors
Cdk inhibitors have been used in clinical trials with limited
success (Malumbres et al., 2008; Lapenna and Giordano,
2009). Among these compounds, only PD0332991, and possibly
P1446A-05 (www.clinicaltrials.gov), are selective for Cdk4 and
Cdk6 with no significant activity on other Cdks (Fry et al.,
2004). Preclinical studies have illustrated that PD0332991 has
inhibitory activity against some human tumor xenografts that
retained pRb expression (Fry et al., 2004). Since K-RasG12V-
driven NSCLC is sensitive to Cdk4 ablation (Figure 7A), wedecided to validate the therapeutic efficacy of PD0332991 in
these mice. K-Raslox/LSLG12Vgeo;RERTert/ert animals were treated
at weaning with 4OHT and monitored by CT 4 months later. Mice
that did not show tumors by CT at this time (CT– mice) were
treated for 30 days (o.i., daily) either with vehicle (n = 4) or with
two doses of the inhibitor, 100 mg/kg (n = 6) and 150 mg/kg
(n = 6), a dose previously shown to be the maximal tolerated
dose (MTD) (Fry et al., 2004). Whereas three out of the four
animals (75%) treated with vehicle developed lesions easily
detectable by CT at the end of the treatment, only two out of
12 mice treated with PD0332991 (17%) developed such lesions
(data not shown).
K-Raslox/LSLG12Vgeo;RERTert/ert animals carrying lung tumors
as determined by CT imaging (CT+ mice) were randomized
and treated either with vehicle or with the above indicated doses
of PD0332991 for 30 days. Mice were monitored for tumor
development by CT at 15 days and at the end of the treatment
(30 days). As illustrated in Figure 8A, animals that receivedCancer Cell 18, 63–73, July 13, 2010 ª2010 Elsevier Inc. 69
Figure 7. Conditional Ablation of Cdk4
Expression Inhibits Progression of K-
RasG12V-Driven NSCLC
(A) Three-dimensional reconstruction of CT
scans from representative K-Raslox/LSLG12Vgeo;
RERTert/ert;Cdk4/frt mice treated with adenoviral
particles expressing control GFP (Ad-GFP) or
Flpe (Ad-Flpe) at the time of treatment and
3 months after treatment.
(B) Quantification of the average tumor volume
of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/frt mice
treated with control Ad-GFP (open bars; n = 5) or
with Ad-Flpe to excise theCdk4frt conditional allele
(solid bars; n = 5). Data shown represent mean ±
SD. *p = 0.014.
(C) Quantification of tumor burden present
in K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/frt mice
3 months after exposure to Ad-GFP (open bars;
n = 5) or Ad-Flpe (solid bars; n = 5). Data shown
represent mean ± SD. *p = 0.049; **p = 0.005;
***p < 0.001.
(D) Partial (top) and uniform (bottom) Cdk4
expression, as determined by IHC analysis with
anti-Cdk4 polyclonal antibodies, in residual
tumors of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/frt
mice treated with Ad-Flpe. The scale bar repre-
sents 100 mm.
(E) The top panels show BrdU incorporation in whole-mount X-Gal-stained lung sections and the bottom panels show senescence-associated b-galactosidase
(SA-b-Gal) staining of lung sections obtained from K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/frt mice 2 weeks after exposure to Ad-GFP or Ad-Flpe. Scale bars repre-
sent 20 mm (top) and 200 mm (bottom).
(F) Western blot analysis of individual tumors (T1 to T4) microdissected from lungs of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/frt mice 3 months after treatment with
Ad-GFP or Ad-Flpe with antibodies specific for Cdk4, p53 phosphorylwithated at residue Ser15, p53, and p19Arf. Migration of the corresponding proteins is indi-
cated by arrowheads. Antibodies against GAPDH were used as loading controls. See also Figure S2.
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day time point and by 4-fold at the end of the experiment. In
contrast, mice treated with the Cdk4 inhibitor only increased
the number of tumors by 1.5-fold (Figure 8A). These differences
became more significant when we measured tumor burden. As
shown in Figure 8B, mice exposed to vehicle increased their
tumor burden by 10-fold after 15 days of observation and
25-fold by the end of the experiment. In contrast, mice exposed
to PD0332991 only increased their tumor burden by 3- to 4-fold
at 15 days and 5- to 6-fold at 30 days (Figure 8B). No significant
differences were observed between the two doses of inhibitor,
suggesting that we may have reached saturating levels even at
the lower dose of 100 mg/kg. We also compared the metabolic
activity of these tumors as criteria for advanced tumor develop-
ment. Whereas 59% of the lesions in the vehicle-treated cohort
were positive for 18F-glucose uptake by positron emission
tomography (PET), only 29% of the mice treated with the inhibitor
displayed 18F-glucose uptake (data not shown).
Finally, we investigated whether exposure to PD0332991
blocked phosphorylation of pRB, the primary substrate for
Cdk4 and elicited a senescence response. As illustrated in
Figures 8C and 8D, PD0332991 efficiently diminished the phos-
phorylation of pRb in the Cdk4-specific Ser807 and Ser811 resi-
dues. However, tumors exposed to PD0332991 did not express
SA-b-Gal. Likewise, none of the tumors tested had increased
phosphorylation on p53P-Ser15 residues or increased p19Arf
expression (data not shown). These results suggest that induc-
tion of a senescence response must require a more robust and70 Cancer Cell 18, 63–73, July 13, 2010 ª2010 Elsevier Inc.possibly sustained inhibition of Cdk4 activity that could be
achieved with the PD0332991 inhibitor.
DISCUSSION
We have assessed the relative contribution of individual inter-
phase Cdks, Cdk2, Cdk4, and Cdk6, to the proliferative and
oncogenic properties conveyed by expression of an endoge-
nous K-RasG12V oncogene. In culture, the absence of any indi-
vidual interphase Cdk cancelled the ability of K-RasG12V-
expressing MEFs to proliferate in limiting serum conditions and
to overcome senescence induced by adaptation to culture
conditions. We obtained similar results using human tumor cell
lines derived from NSCLCs providing that these tumor cells
also carry K-RAS oncogenes. The lack of specificity for any
particular CDK suggests that K-RAS signaling in these tumor
cells demands increased overall CDK activity, rather than phos-
phorylation of selective substrates.
In principle, these findings raised the possibility that limited
inhibition of overall interphase CDK activity may have selective
therapeutic effect on K-RAS-driven lung tumors. Yet, these
in vitro studies could not be fully paralleled in vivo. Expression
of a resident K-RasG12V oncogene in mice null for Cdk6 resulted
in efficient induction of NSCLCs. Likewise, absence of Cdk2 did
not prevent tumor formation. In this case, however, there was
a limited reduction in tumor burden that resulted in increased
life span. These findings are similar to those currently observed
with a number of targeted therapies in clinical trials. However,
Figure 8. A Selective Cdk4 Inhibitor,
PD0332991, Inhibits K-RasG12V-Driven
NSCLC
(A) Number of CT+ tumors in 5-month-old tumor-
bearing K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+
mice (exposed to 4OHT at weaning) treated daily
for 30 days with vehicle (solid bars; n = 7), or
with an oral dose of 100 mg/kg (open bars; n = 6)
or 150 mg/kg (gray bars; n = 6) of PD0332991.
Data shown represent mean ± SD.
(B) Increased tumor burden, determined by CT
analysis, during a 30 day period in 5-month-
old tumor-bearing K-Raslox/LSLG12Vgeo;RERTert/ert;
Cdk4+/+ mice treated as indicated above. Total
tumor burden at the beginning of the experiment
was 9.68 mm3, 5.35 mm3, and 9.71 mm3 for
mice treated with either vehicle (solid bars; n =
7), 100 mg/kg (open bars; n = 6), and 150 mg/kg
(gray bars; n = 6) of PD0332991, respectively.
Data shown represent mean ± SD. *p = 0.045.
(C) Immunohistochemical analysis of phosphory-
lated pRb at Cdk4-specific residues Ser807/
811 in lung sections of K-Raslox/LSLG12Vgeo;
RERTert/ert;Cdk4+/+ mice 1 month after treatment with vehicle (left) or 150 mg/kg of PD0332991 (right). Scale bar: 200 mm. Insert shows a 103 magnification
of a representative area.
(D) Western blot analysis of individual tumors microdissected from lungs of K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4+/+ mice 1 month after treatment with either
vehicle (T1–T3) or 150 mg/kg of PD0332991 (T1–T6) with antibodies specific for pRb phosphorylated at residues Ser807/811. Antibodies against GAPDH
were used as loading controls. Migration of the corresponding proteins is indicated by arrowheads.
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suggests that inhibition of CDK2 may not yield significant thera-
peutic benefit for NSCLC patients.
On the contrary, absence of Cdk4 had major consequences
for tumor growth. K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ mice
developed very few tumors, all of them of benign nature. These
observations were a consequence of an unexpected synthetic
lethal interaction between the K-RasG12V oncogene and the
absence of Cdk4 expression in lung cells that resulted in the
immediate onset of senescence. This response was observed
during the initial rounds of K-RasG12V-induced cell division, well
before the appearance of hyperplastic lesions or adenomas.
Moreover, this response was exquisitely selective for tissue
type (lung) and interphase Cdk (Cdk4). Expression of K-RasG12V
in other tissues devoid of Cdk4, including colon and pancreas,
two tissues known to yield K-Ras oncogene-driven tumors in
both mice and humans, did not induce senescence. Likewise,
we did not observe a K-RasG12V-driven senescence response
in lungs of mice lacking Cdk2. The reason why lung cells are so
dependent on Cdk4 for K-RasG12V-driven proliferation is
unknown, given that normal lung development does not require
Cdk4 expression (Rane et al., 1999; Tsutsui et al., 1999).
Recently, Campaner et al. (2010) have demonstrated that lack
of Cdk2 promotes senescence of c-Myc-driven tumors. Thus,
individual interphase Cdks may be specifically required for devel-
opment of certain tumors depending on the tissue of origin and
the driving oncogenic insults (Malumbres and Barbacid, 2009).
Given that Cdk4 null mice occasionally developed benign
adenomas, lung cells must have alternative mechanisms to
bypass K-RasG12V-induced senescence. It is possible that tumor
initiating cells in the lung may not be a homogeneous population
and respond differently to K-RasG12V expression. Thus, tumor-
initiating cells may include a small subpopulation resistant toK-RasG12V-induced senescence regardless of the expression
of Cdk4. These K-Raslox/LSLG12Vgeo;RERTert/ert;Cdk4/ cells
that escape initial senescence and form adenomas eventually
expressed senescence markers as previously described in
lesions with a full Cdk complement (Collado et al., 2005; Prieur
and Peeper, 2008). Interestingly, the absence of Cdk4 must
help to re-enforce this antitumor barrier since Cdk4/
adenomas do not progress to malignant adenocarcinomas.
The induction of a senescence response in CT+ tumors upon
cleavage of the conditional Cdk4frt allele may have important
therapeutic implications for human NSCLC. Conditional ablation
of Cdk4 expression in CT+ tumors induces widespread senes-
cence that significantly reduces cell proliferation, leading in
most cases to disappearance of the tumor. Indeed, all actively
growing tumors in Adeno-Flpe-treated K-Raslox/LSLG12Vgeo;
RERTert/ert;Cdk4/frt mice invariably carried an intact Cdk4frt
allele and expressed Cdk4. Hence, indicating that tumor
progression required continuous Cdk4 expression. Loss of
Cdk4 in CT+ tumors also triggers an immune response likely to
contribute to the observed antitumoral effect. Ablation of Cdk4
in mouse models carrying additional mutations such as loss of
p53 should provide clinically relevant information as whether
tumor cells that have accumulated other genetic alterations
retain the capacity of entering senescence upon ablation of
Cdk4 expression.
Recent studies have used high-throughput RNAi libraries to
identify synthetic lethal interactions between the TBK1 and
STK33 kinases with K-RAS oncogenes (Barbie et al., 2009;
Scholl et al., 2009). One of these studies also identified synthetic
lethal interactions with several Cdks including CDK1, CDK2,
CDK6, CDK7, and CDK8, but not CDK4 (Barbie et al., 2009). It
is possible that the RNAi library may not contain optimal
sequences against CDK4. Based on our own findings,Cancer Cell 18, 63–73, July 13, 2010 ª2010 Elsevier Inc. 71
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always be validated in vivo (e.g., loss of Cdk2 and Cdk6 in K-
RAS-expressing NSCLC cell lines). Use of genetically modified
mouse models that closely recapitulate the natural history of
human tumors should strengthen the value of potential synthetic
lethal interactions with regard of their potential use in clinical
trials.
It could be argued that ablating expression of a target may not
mimic inhibition of its biological activity. Conditional knockin
strategies may eventually circumvent this problem. Ultimately,
however, the use of selective inhibitors, when available, may
be the most direct approach. Here, we have shown that a
Cdk4/Cdk6 selective inhibitor, PD0332991, had significant
therapeutic activity in K-RasG12V-induced NSCLC. As expected,
this inhibitor blocked Cdk4-mediated phosphorylation of pRb.
Yet, it failed to induce the robust senescence response observed
upon genetic ablation of the Cdk4 locus. Thus, it is probable
that in order to induce a senescence response, Cdk4 inhibitors
must induce a more robust and durable Cdk4 inhibition. Indeed,
it is possible that induction of senescence might be used as
a biomarker for adequate Cdk4 inhibition in future clinical
trials. So far, PD0332991 has failed to show activity in phase I
clinical trials against undefined advanced solid tumors, non-
Hodgkin’s lymphoma, and mantle cell lymphoma. Additional
clinical trials on multiple myeloma and breast cancer in combina-
tion with other drugs are currently ongoing (http://www.cancer.
gov/). The results described here suggest that PD0332991,
as well as other potential CDK4 selective inhibitors should be
tested in NSCLC positive for K-RAS oncogenes, either alone
or in combination with other drugs. Our findings should also
encourage renewed efforts to design more potent and specific
Cdk4 inhibitors.
EXPERIMENTAL PROCEDURES
Cell Culture Assays
MEFs were isolated from E13.5 embryos and propagated according to stan-
dard 3T3 protocols. For proliferation assays, 5 3 104 cells were plated on
six-well plates in duplicate in DMEM supplemented with 2% fetal calf serum.
Human NSCLC cell lines were purchased from the ATCC. For proliferation
assays 13 103 cells were plated in 96-well plates and their growth rate deter-
mined by the MTT cell proliferation kit (Roche).
Mice
The K-Ras+/LSLG12Vgeo;RERTert/ert, Cdk2lox/lox, Cdk2/, Cdk4frt/frt, Cdk4/,
and Cdk6/strains have been previously described (Guerra et al., 2003;
Ortega et al., 2003; Malumbres et al., 2004; Barrie`re et al., 2007). K-Raslox/lox
mice will be described elsewhere. Compound strains were generated by stan-
dard crosses. CreERT2-mediated recombination was induced at weaning by
intraperitoneal administration of 4-OHT (1 mg/dose). Elimination of the condi-
tional Cdk4frt allele was achieved by tail vein inoculation of adenoviral particles
(5 3 109 plaque-forming unit [pfu]) expressing the Flpe recombinase. Adeno-
viruses expressing GFP were used as controls at the same dose. All animal
experiments were approved by the CNIO Ethical Committee and performed
in accordance with the guidelines stated in The International Guiding Principles
for Biomedical Research involving Animals, developed by the Council for Inter-
national Organizations of Medical Sciences (CIOMS).
Histopathology and Immunohistochemistry
Mice were sacrificed at the time points specified in the text. For routine histo-
logical inspection lung lobes were fixed in 10% buffered formalin (Sigma) and
embedded in paraffin. For quantification and classification of tumor lesions,
lung lobes were processed for whole-mount X-Gal staining (Guerra et al.,72 Cancer Cell 18, 63–73, July 13, 2010 ª2010 Elsevier Inc.2003). Whole-mount stained lung lobes were serially sectioned and tumors
counted classified according to histopathological grading (Jackson et al.,
2005). For endogenous SA-b-galactosidase detection, lung lobes were
snap-frozen in O.C.T. (Sakura) and processed on 10 mM cryostat sections
with a Senescence b-Galactosidase staining kit (Cell Signaling) in accordance
with the manufacturer’s recommendations. Counterstaining of cryostat
sections was performed with nuclear fast red. Antibodies used for immunohis-
tochemistry analysis included anti Cdk2, Cdk4, and Cdk6 rabbit polyclonal
antibodies generated in our own laboratory as well anti-Cyclin D1 (Neo-
markers), g-H2AX (Millipore) and BrdU (GE Healthcare).
Western Blot Analysis
Tissue samples and cell pellets were processed as previously described
(Barrie`re et al., 2007). The following primary antibodies were used: anti-Cdk2
and Cdk4, p19Arf (Upstate), p53 (Novocastra), Ser15-p53 (Cell Signaling),
pRb-S807/811 (Cell Signaling), and GAPDH (Sigma).
PD0332991 Treatment
The Cdk4 inhibitor was dissolved in a stock solution of sodium lactate buffer
(50 mM [pH 4]) and was administered daily during 1 month at 150 mg/kg or
100 mg/kg by gavage. The vehicle control group received an equivalent
volume of sodium lactate buffer solution.
Computed Tomography
Mice were anesthetized with a continuous flow of 1% to 3% isoflurane/oxygen
mixture (2 liters/min), and the chest area was able to be imaged at one time
with the GE eXplore Locus micro-CT scanner (GE Healthcare). The isotropic
resolution of this instrument is 45 mm. The micro-CT image acquisition
consisted of 400 projections collected in one full rotation of the gantry
in 10 min. The image acquisition was not respiratory-gated. The X-ray tube
settings were 80 kV and 450 mA. The resulting raw data were reconstructed
to a final image volume of 8753 8753 465 slices at 93 mm3 voxel dimensions.
The reconstructed slices were output in the CT manufacturer’s raw format and
were corrected equal to Hounsfield units. The reconstructed images were
viewed and analyzed with MicroView analysis software (GE Healthcare).
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and can be found with this
article online at doi:10.1016/j.ccr.2010.05.025.
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